



SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

Date: February 12, 2024

To,
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Sub: Investor Presentation for the Quarter Ended December 31, 2023

Dear Sir/Madam,

Please find enclosed herewith Revised Investor Presentation of Sanjivani Paranteral Limited highlighting the performance of the Company during the quarter ended on December 31, 2023.

We are requested to kindly take the same on record.

Thanking You

Yours Faithfully
For Sanjivani Paranteral Limited

Compliance Officer.



Encl: As above



Sanjivani Paranteral Ltd

Investor Presentation

Q3 & 9M FY24



TABLE OF CONTENT

ABOUT THE COMPANY	—	3
CDMO KEY CLIENTS	—	8
COMPANY'S SEGMENT & REVENUE MIX	—	10
GLOBAL FOOTPRINT	—	14
PRODUCT PORTFOLIO	—	16
FINANCIALS	—	20



ABOUT THE COMPANY

Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.



**WHO-GMP/ DIGEMID /
DDA Nepal**

Certified Plants



2

Manufacturing Facilities



25 Countries

Geographical Reach



~70%

Exports Revenue



25+ years

Experience



720 million

Annual Tablet Capacity



84 million

Annual Ampoules Capacity



12 million

Annual Liquid injectables
Capacity



12 million

Annual Ointment/Cream
Capacity



24 million

Annual B Lactam Dry
Syrup Capacity



14.4 million

Annual Topical Solution
Capacity



48 million

Annual Vial Capacity



120 million

Annual B Lactam Tablet
Capacity



180 million

Annual B Lactam Capsule
Capacity



72 million

Annual Capsule Capacity

VISION



To be one of India's best research-based pharmaceutical companies, through focus on quality and customer satisfaction


To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & team members To grow the company on the foundation of Passion, Performance & Partnership

MISSION



Creating a world-class organization offering products, services & paradigms that open up new worlds of opportunities

VALUES



1. Quality

Products that we are proud of

2. Customer Satisfaction

Exceeding Customer expectations is our success-mantra

3. Growth for all stakeholders

Exceeding Customer expectations is our success-mantra

4. Professionalism

People you love to work with.
A culture of innovative thinking, backed by disciplined execution

01

Having a small base in India,
we are very nimble and
agile.

02

Quick decisions
making powers

03

Long history in the industry enables a
respectable position due to which
talent and good suppliers want to
associate with us

04

Pioneers in injectable manufacturing in India
during times when regulations weren't as strict.
The company has seen the evolution of the
regulations and it makes it easy for us to predict

05

History of injectable manufacturing also gives a
vast knowledge of how different manufacturing
processes work and which is more efficient.


Experienced Management



Mr. Ashwani Khemka
Chairman & Managing Director



Mrs. Mrunmai Sarvankar
Director




Mr. Shrenikkumar P. Solanki
Director



Mr. Srivardhan Khemka
Director



Ms. Monika A. Singhani
Director



Mr. Hitesh Khona
Chief Financial Officer



CDMO KEY CLIENTS

Injectables:



Oral & Nutraceuticals:







**COMPANY'S
SEGMENT & REVENUE
MIX**

Product Category Mix (%)

Q3 FY24




Q3 FY23




Geographical Mix (%)

Q3 FY24




Q3 FY23




Region-wise Mix (%)

Q3 FY24




Q3 FY23





GLOBAL FOOTPRINT





PRODUCT PORTFOLIO



Products Portfolio (1/2)

Urologics



Anesthetics



Anesthetics



Anti Convulsants



Anti Thyroid Agent



Anti Fungal



Anti Emetics



Anti Depressants



Anti Histamines



Anti Diabetic



Anti-lepemic Agent



Anti Fibrinolytics



Anti-bacterials



Anti-spasmodic



Anti Hypertensive Agent



Vitamin Supplements



Skeletal Muscle Relaxant



Analgesic And Anti Histaminic



Products Portfolio (2/2)

Non-opioid Analgesics



Antacids



Antiseptics



Nsaids



Corticosteroids



Diuretics



Immunosuppressants



Laxative



Narcotic



Hormone



Topical Corticosteroids



Anti Anxiety



Antibiotic



Antipsychotic



Anti Viral



Narcotics



Anti- Muscle Relaxant





1

Infusion
injectables

2

IV Sets
(medical device)

3

Pre-filled syringe -
enoxaparin, Sodium
hyalarunate

4

Complex
injectables - long acting,
emulsions, etc




FINANCIALS




Segment-wise Revenue (Injectables, Oral & Nutraceuticals)

Injectables




Orals




Rs. In Mn.

Nutraceuticals




Quarterly Financials - Revenue, EBITDA & Margin, PAT & Margin

Revenue




EBIDTA & EBIDTA Margin


Rs. In Mn.



PBT & PBT Margin




PAT & PAT Margin




Q3 & 9M FY24 Profit & Loss Statement

Particulars (Rs. In Mn.)	Q3 FY24	Q3 FY23	YoY%	Q2 FY24	QoQ%	9M FY24	9M FY23	YoY%
Revenue From Operations	149.6	91.2	64%	140.0	7%	415.5	273.7	52%
Cost of Goods Sold	79.8	57.1	40%	89.6	-11%	235.3	150.7	56%
Gross Profit	69.9	34.1	105%	50.4	39%	180.1	123.0	46%
Gross Margin %	46.7%	37.4%	931bps	36.0%	1071bps	43.4%	45.0%	-160bps
Employee Expenses	12.0	6.0	101%	8.7	37%	29.6	19.4	53%
Other Expenses	38.3	18.9	102%	20.5	87%	89.7	61.5	46%
EBITDA	19.6	9.2	112%	21.1	-7%	60.8	42.1	44%
EBITDA Margin %	13.1%	10.1%	298bps	15.1%	-201bps	14.6%	15.4%	-75bps
Depreciation	2.4	2.3	4%	2.3	1%	7.0	6.6	5%
Other Income	2.5	3.1	-18%	1.5	69%	4.6	5.9	-22%
Financial Cost	0.8	0.5	43%	0.5	67%	1.7	2.0	-17%
PBT	19.0	9.5	99%	19.9	-4%	56.9	39.5	44%
Tax	2.5	0	-	2.8	-11%	7.8	4.3	81%
PAT	16.5	9.5	73%	17.1	-3%	49.1	35.1	40%
PAT Margin %	11.0%	10.4%	59bps	12.2%	-115bps	11.8%	12.8%	-103bps
EPS	1.65	0.95	74%	1.71	-4%	4.91	3.52	39%

Long Term Growth Drivers




Shareholding Pattern



Stock Information (as on 31st December 2023)

Market Cap. (in crores)	178.3
Stock Price	180.1
52 Week (High / Low)	180.1 / 25.34
BSE – Symbol	531569
Free Float (No. of Shares)	67,65,239
Average Daily Volume (3months) - BSE	23.0k





THANK YOU




Sanjivani Paranteral Limited

205, P.N.Kothari Industrial Estate, L.B.S.
Marg Bhandup (W), Mumbai- 400078, India.

Ph: +91-22-20812600 / 25620515

Email: corporate@sanjivani.co.in



Vijay Gyanchandani / Jill Chandrani

+91 9619438448 / +91 7506023955

Email: vijay@s-ancial.com / jill@s-ancial.com

215, Shivshakti Industrial Estate,
J.R Boricha Marg, Lower Parel (E) Mumbai - 400011

